Chronic eosinophilic leukemia with a novel JAK1 mutation responds well to the JAK1/2 inhibitor ruxolitinib.

作者信息

Wei Qing, Xu Jie

机构信息

MD Anderson Cancer Center.

出版信息

Blood. 2024 Jul 11;144(2):238. doi: 10.1182/blood.2024024626.

DOI:10.1182/blood.2024024626

PMID:38990537

Abstract

摘要

相似文献

Chronic eosinophilic leukemia with a novel JAK1 mutation responds well to the JAK1/2 inhibitor ruxolitinib.

Blood. 2024 Jul 11;144(2):238. doi: 10.1182/blood.2024024626.

Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation.

Leuk Lymphoma. 2019 Jul;60(7):1626-1631. doi: 10.1080/10428194.2019.1594220. Epub 2019 Apr 18.

Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children.

J Allergy Clin Immunol. 2016 Dec;138(6):1752-1755. doi: 10.1016/j.jaci.2016.07.015. Epub 2016 Aug 20.

A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia.

Clin Lymphoma Myeloma Leuk. 2015 Mar;15(3):171-6. doi: 10.1016/j.clml.2014.08.003. Epub 2014 Sep 17.

A novel activating JAK1 mutation in chronic eosinophilic leukemia.

Blood Adv. 2021 Sep 28;5(18):3581-3586. doi: 10.1182/bloodadvances.2021004237.

JAK2 inhibitors for myeloproliferative neoplasms: what is next?

Blood. 2017 Jul 13;130(2):115-125. doi: 10.1182/blood-2017-04-742288. Epub 2017 May 12.

The role of JAK1/2 inhibitors in the treatment of chronic myeloproliferative neoplasms.

Am Soc Clin Oncol Educ Book. 2013:301-5. doi: 10.14694/EdBook_AM.2013.33.301.

Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect.

PLoS One. 2014 Oct 7;9(10):e109799. doi: 10.1371/journal.pone.0109799. eCollection 2014.

Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent mutations in chronic neutrophilic leukemia.

Haematologica. 2017 Jun;102(6):e238-e240. doi: 10.3324/haematol.2017.163790. Epub 2017 Mar 16.

Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia.

Blood. 2012 Oct 25;120(17):3510-8. doi: 10.1182/blood-2012-03-415448. Epub 2012 Sep 6.

引用本文的文献

Molecular Dynamics Simulation Analysis of JAK1 Initial Activation: Phosphorylation-Induced Conformational Dynamics and Domain Interactions.

Life (Basel). 2025 Aug 19;15(8):1316. doi: 10.3390/life15081316.

Malignant JAK-signaling: at the interface of inflammation and malignant transformation.

Leukemia. 2025 May;39(5):1011-1030. doi: 10.1038/s41375-025-02569-8. Epub 2025 Mar 26.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Suppr
超能文献

Chronic eosinophilic leukemia with a novel JAK1 mutation responds well to the JAK1/2 inhibitor ruxolitinib.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

Suppr超能文献

Chronic eosinophilic leukemia with a novel JAK1 mutation responds well to the JAK1/2 inhibitor ruxolitinib.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

Suppr
超能文献